Exelixis Inc (EXEL)

Add to Watchlists
Create an Alert
Quickflows
18.73 +0.31  +1.68% NASDAQ Nov 25, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All EXEL News

News

View All Events

Events

Date Type Description
02/25/2021 Earnings Exelixis Inc Fourth Quarter Earnings for 2020 Release
02/25/2021 17:00 EST Misc Exelixis Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Exelixis Inc Third Quarter Earnings Result for 2020
11/05/2020 17:00 EST Misc Exelixis Inc Third Quarter Earnings Conference Call for 2020
08/06/2020 17:30 EDT Misc Exelixis Inc Second Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Exelixis Inc Second Quarter Earnings Result for 2020
05/20/2020 10:00 PDT Misc Exelixis Inc Annual General Meeting for 2019
05/05/2020 17:00 EDT Misc Exelixis Inc First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Exelixis Inc First Quarter Earnings Result for 2020
02/25/2020 17:00 EST Misc Exelixis Inc Fourth Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 957.80M
Total Expenses (TTM) 794.72M
Net Income (TTM) 152.14M

Balance Sheet View Statement

Total Assets (Quarterly) 2.111B
Total Liabilities (Quarterly) 259.01M
Shareholders Equity (Quarterly) 1.852B

Cash Flow Statement View Statement

Cash from Operations (TTM) 333.71M
Cash from Investing (TTM) -231.91M
Cash from Financing (TTM) -9.438M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.exelixis.com
  • Investor Relations URL: http://www.exelixis.com/investors-media
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Feb. 25, 2021
  • Last Earnings Release: Nov. 05, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 18.73
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
VLIIX Value Line Capital Appreciation Instl 3.66%
VLLIX Value Line Larger Companies Focus Instl 3.59%
IDNA iShares Genomics Immnlgy & Hlthcr ETF 3.40%
APSRX Fiera Capital Small/Mid-Cap Growth Inv 2.37%
FIJYX Fidelity Advisor® Biotechnology Z 2.27%
IBBJ Defiance Nasdaq Junior Biotechnology ETF 1.81%
PXSAX Pax Small Cap A 1.69%
FBIOX Fidelity® Select Biotechnology 1.38%
HQL Tekla Life Sciences Investors 1.11%
HQH Tekla Healthcare Investors 1.00%

Comparables

Edit
BMY Bristol-Myers Squibb Co
PFE Pfizer Inc
ILMN Illumina Inc
ALXN Alexion Pharmaceuticals Inc
BMRN Biomarin Pharmaceutical Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.